Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Ionis Pharmaceuticals Inc today announced that it has entered into a license agreement with Otsuka, under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, which is an investigational prophylactic treatment for hereditary angioedema (HAE).
Ionis will maintain responsibility for the non-clinical and clinical development of donidalorsen, and Otsuka will be responsible for European regulatory filings and commercialization.
Ionis plans to independently launch donidalorsen in the U.S. if approved, as part of the company’s strategy to deliver a steady flow of wholly owned medicines to patients.
Brett P. Monia, PhD, Ionis’ Chief Executive Officer, said: “We are excited to collaborate with Otsuka given their proven results in bringing rare disease medicines to patients in Europe. This agreement is aligned with our strategy to initially focus our commercialization efforts on the U.S. market. We are encouraged by the strong product profile of donidalorsen to date and look forward to reporting pivotal topline Phase 3 donidalorsen results in HAE in the first half of next year.”
(Source: Ionis)
